Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Companies

Gilgamesh

Gilgamesh Pharmaceuticals, Inc.

HQ
United States
Status
acquired
Listing
Private

sec.govregistryverified 2026-09-25

Notes on the record

Target in D003-abbvie-gilgamesh-2025 and counterparty to the 2024 option in D004-abbvie-gilgamesh-option-2024. Lead programme bretisilocin (GM-2505), renamed ABBV-2505 after the acquisition closed in October 2025. Added 2026-09-25 so the deal tape can print its short name.

Assets

No asset in data/assets.csv names this company as owner.

Registered trials

No row in data/trials.csv resolves to this company's assets.

Deals

In the briefing

No published issue carries the GILGAMESH tag.